Literature DB >> 11505438

Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro.

C Caussin-Schwemling1, C Schmitt, F Stoll-Keller.   

Abstract

Hepatitis C virus (HCV) is essentially hepatotropic, but clinical observations based on quasispecies composition in different compartments or on viral RNA detection in cells suggest that the virus is able to infect and persist in cells other than liver cells. It was shown previously that peripheral blood mononuclear cells (PBMCs) are permissive to HCV replication in vitro but at a very low rate. Since different viruses associated with chronic infections are known to persist in monocyte/macrophages, it is important to determine whether these mononuclear blood cells are susceptible preferentially to HCV. In order to study HCV interaction with monocytes/macrophages, these cells were isolated from the blood of healthy donors and incubated with HCV genotype 1b positive sera. The detection by RT-PCR of the positive- and negative-strand RNA in the cells at different times and the increase in the amount of intracellular viral RNA measured by the branched DNA assay suggest that monocyte/macrophages can support HCV RNA replication. The rate, however, is very low. The analysis of hypervariable region 1 (HVR-1) nucleotide sequences indicated that some minor variant present in the inoculum might display a specific tropism for the monocytes/macrophages. These results provide evidence that human monocytes/macrophages might represent a reservoir for HCV. This cell tropism may be a crucial factor in the pathogenesis of hepatitis C. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505438     DOI: 10.1002/jmv.1095

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

Review 1.  Macrophages in hepatitis B and hepatitis C virus infections.

Authors:  Mathis Heydtmann
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

2.  Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.

Authors:  Jason T Blackard; Gang Ma; Satarupa Sengupta; Christina M Martin; Eleanor A Powell; M Tarek Shata; Kenneth E Sherman
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

3.  Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Baré.

Authors:  Patricia Baré
Journal:  World J Hepatol       Date:  2009-10-31

4.  Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.

Authors:  Kenneth E Sherman; Norah J Shire; Susan D Rouster; Marion G Peters; Margaret James Koziel; Raymond T Chung; Paul S Horn
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

5.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

Review 6.  Role of macrophages and monocytes in hepatitis C virus infections.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 7.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 8.  Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Authors:  Elham Shirvani-Dastgerdi; Robert E Schwartz; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2016-08-06       Impact factor: 7.090

Review 9.  Cognitive dysfunction in chronic hepatitis C: a review.

Authors:  William Perry; Robin C Hilsabeck; Tarek I Hassanein
Journal:  Dig Dis Sci       Date:  2007-08-17       Impact factor: 3.199

10.  Hepatitis C virus neuroinvasion: identification of infected cells.

Authors:  Jeffrey Wilkinson; Marek Radkowski; Tomasz Laskus
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.